Jeff Yass’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-227,800
| Closed | -$24.3M | – | 13732 |
|
|
2025
Q3 | $24.3M | Sell |
227,800
-193,600
| -46% | -$20.2M | ﹤0.01% | 1998 |
|
|
2025
Q2 | $39.9M | Sell |
421,400
-54,800
| -12% | -$4.06M | 0.01% | 1333 |
|
|
2025
Q1 | $30.2M | Buy |
476,200
+255,600
| +116% | +$15.3M | 0.01% | 1381 |
|
|
2024
Q4 | $10.2M | Sell |
220,600
-18,700
| -8% | -$702K | ﹤0.01% | 2636 |
|
|
2024
Q3 | $6.88M | Buy |
239,300
+215,100
| +889% | +$5.29M | ﹤0.01% | 3114 |
|
|
2024
Q2 | $350K | Sell |
24,200
-22,000
| -48% | -$321K | ﹤0.01% | 9117 |
|
|
2024
Q1 | $743K | Buy |
46,200
+100
| +0.2% | +$1.73K | ﹤0.01% | 7574 |
|
|
2023
Q4 | $916K | Buy |
46,100
+8,000
| +21% | +$118K | ﹤0.01% | 7192 |
|
|
2023
Q3 | $621K | Sell |
38,100
-15,300
| -29% | -$295K | ﹤0.01% | 7724 |
|
|
2023
Q2 | $1.13M | Buy |
53,400
+1,800
| +3% | +$38.4K | ﹤0.01% | 6395 |
|
|
2023
Q1 | $1.04M | Sell |
51,600
-107,300
| -68% | -$2.32M | ﹤0.01% | 6722 |
|
|
2022
Q4 | $4.15M | Sell |
158,900
-143,400
| -47% | -$1.91M | ﹤0.01% | 3518 |
|
|
2022
Q3 | $3.09M | Buy |
302,300
+256,000
| +553% | +$2.16M | ﹤0.01% | 4023 |
|
|
2022
Q2 | $194K | Buy |
+46,300
| New | +$198K | ﹤0.01% | 10688 |
|
Other funds holding VRNA
Jeff Yass's VRNA Position: Q2 2025 in Review
Jeff Yass sold out of Verona Pharma (VRNA) in Q2 2025, closing a stake of 33,655 shares — an estimated $2.49M sold.
Jeff Yass first reported a position in VRNA in Q4 2019 and held it in 12 quarters. The position peaked at $5.17M in Q4 2024. 292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.
- Jeff Yass reported no remaining Verona Pharma position as of Q2 2025 after selling out during the quarter.
- Jeff Yass sold 33,655 Verona Pharma shares in Q2 2025, an estimated $2.49M.
- Jeff Yass first reported a position in Verona Pharma in Q4 2019 and held it in 12 quarters.
- Jeff Yass's Verona Pharma position peaked at $5.17M in Q4 2024.
- 292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.